The biotech firm reported a wider net loss of $60.7 million for Q1 2026, extending its cash runway through 2027.
MapLight Therapeutics reported a first-quarter GAAP loss of $1.34 per share, reflecting a net loss of $60.7 million. The figure compares with a $22.3 million net loss in the same period of 2025, marking a deterioration in financial performance.
The company ended the quarter with $395.2 million in cash, cash equivalents, and investments. Management expects this liquidity to fund operations through 2027, providing a buffer for ongoing research and development efforts.